UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
March 3, 2009
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
Commission File No. 001-33057
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
| |
|
|
| Delaware
|
|
76-0837053 |
(State Or Other Jurisdiction Of
Incorporation Or Organization)
|
|
(IRS Employer
Identification No.) |
355 Alhambra Circle, Suite 1370
Coral Gables, Florida 33134
(Address Of Principal Executive Offices)
(305) 529-2522
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 8.01 Other Events
On March 3, 2009, the Company issued a press release announcing its intention to halt enrollment of
new subjects into its ongoing U.S. Phase II trial evaluating CPP-109 for the treatment of
methamphetamine addiction and instead convert that trial into a smaller proof-of-concept study
treating the approximately 55 patients currently enrolled in the trial for the thirteen week active
phase as described in the protocol. A copy of the Company’s press release is Exhibit 99.1 to this
Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
| |
99.1 |
|
Press release issued by the Company on March 3, 2009 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
Catalyst Pharmaceutical Partners, Inc.
|
|
| |
By: |
/s/ Patrick J. McEnany
|
|
| |
|
Patrick J. McEnany |
|
| |
|
Chairman, President and CEO |
|
| |
Dated: March 5, 2009
3